Advances in Anti-EGFR Therapy of Metastatic Colorectal Cancer
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: closed (15 September 2021) | Viewed by 333
Special Issue Editor
Interests: colorectal cancer; phase III studies; HIV-related cancers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The survival of patients affected by metastatic colorectal cancer (mCRC) has improved since 1) the introduction of biologic treatments and 2) the selection of patients on a genetic basis. In fact, it is well known that tumors bearing specific activating mutations in the KRAS (Kirsten Rat Sarcoma) oncogene do not respond to anti-EGFR (Epidermal Growth Factor Receptor) antibodies (panitumumab and cetuximab), which block and prevent growth factors from binding. In fact, in these cases, EGFR downstream signals work independently from the ligand engagement. However, panitumumab and cetuximab are two different drugs; the first is a fully humanized IgG2, the second a chimeric mouse–human IgG1. Recent data have shown that an immune-mediated mechanism could account for the anti-tumor activity of cetuximab being able to activate, much more effectively than panitumumab, the NK-mediated ADCC (Antibody Dependent Cellular Cytotoxicity) against tumor cells.
The aim of this Special Issue is to describe the innovative and less explored topics concerning the anti-EGFR treatment of mCRC, focusing on the following:
- EGFR inhibition in mCRC—beyond the antibodies-based therapy;
- Genetic profiling of the EGFR pathway—new approaches to ameliorate patient selection;
- Links between anti-EGFR treatments and immune system activation.
One review on “where do we stand and where do we go” is also welcome.
Dr. Guglielmo Nasti
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cetuximab
- panitumumab
- EGFR
- metastatic colorectal cancer
- gastrointestinal oncology.
